Spiers ASD, Goldman JM, Catovsky D, Costello C, Buskard NA, Galton DAG (1977) Multiple-drug chemotherapy for acute leukemia: the TRAMPCOL regimen: results in 86 patients. Cancer 40: 20–9Spiers ASD, Goldman JM, Catovsky D, Costello C, Buskard NA, Galton DAG: Multiple-drug chemo...
Screening the Lopac library for drug activity in a panel of leukemia (acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia) and PBMC cultures. The overall screening results are displayed in (a) and expressed as percent inhibition (PI). In (b) the top twenty-five hits...
A. et al. SGN-CD33A: preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody–drug conjugate for the treatment of acute myeloid leukemia (AML). Cancer Res. 75, abstr. DDT02-04 (2015). Article CAS Google Scholar Panowski, S., Bhakta, S., Raab,...
Subsequently, the predominant impact of cytogenetics on probability of response to treatment and survival was first illustrated in leukemia. The power of a single drug to change the natural history of a disease was noted in acute myelogenous leukemia, in which a previously incurable disease was ...
The drug is designed to treat patients with a form of acute myeloid leukemia in which the enzyme isocitrate dehydrogenase 1 (IDH1) is mutated, researchers at the University of Texas MD Anderson Cancer Center said. IDH1 mutations occur in 6 to 10 percent of AML patients. ...
Radiotherapy is important in the treatment of leukemia and lymphoma of children. In acute lymphocytic leukemia administration of cranial irradiation early during chemotherapy-induced remission prevents initial meningeal relapse. When cra... DB Czarnecki - 《Archives of Dermatology》 被引量: 18发表: 1982...
Preliminary findings from the MB-106 trial support the potential benefit of annamycin/cytarabine in patients with acute myeloid leukemia. Treatment with annamycin in combination with cytarabine for those with relapsed/refractory AML is under assessment as part of the phase 1b/2 MB-106 trial (N...
Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia Combining new therapeutics with all-trans-retinoic acid (ATRA) could improve the efficiency of acute myeloid leukemia (AML) treatment. Modeling the process... S Novikova,T Tolstova,L Kurbatov,... - 《International Journal of Mole...
et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114, 257–260 (2009). CAS PubMed Google Scholar Pettersson, F. et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker ...
Differentiation therapy is attracting increasing interest in cancer as it can be more specific than conventional chemotherapy approaches, and it has offered new treatment options for some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid. However, there is a pressing...